595 participants
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-06-30
- Start Date:
- 2019-07-24
- Completion:
- 2025-06-06
Conditions
- Urinary Bladder Cancer, Muscle-invasive
Interventions
- DRUG
- PROCEDURE